Hikma Pharmaceuticals Plc’s (HIK) “Neutral” Rating Reiterated at JPMorgan Chase & Co.
Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “neutral” rating reaffirmed by investment analysts at JPMorgan Chase & Co. in a research note issued on Wednesday, StockTargetPrices.com reports. They currently have a GBX 2,400 ($30.21) price objective on the stock. JPMorgan Chase & Co.’s price target points to a potential upside of 30.08% from the company’s current price.
Other equities analysts have also issued reports about the company. Numis Securities Ltd lowered Hikma Pharmaceuticals Plc to an “add” rating and set a GBX 2,350 ($29.58) price target on the stock. in a research note on Friday, March 10th. Peel Hunt restated a “buy” rating and set a GBX 2,340 ($29.45) price target on shares of Hikma Pharmaceuticals Plc in a research note on Friday, February 24th. Jefferies Group LLC lifted their price objective on Hikma Pharmaceuticals Plc from GBX 2,065 ($25.99) to GBX 2,162 ($27.21) and gave the company a “buy” rating in a report on Tuesday, January 17th. AlphaValue reaffirmed a “buy” rating and set a GBX 2,431 ($30.60) price objective on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, November 30th. Finally, HSBC Holdings plc downgraded Hikma Pharmaceuticals Plc to a “reduce” rating and set a GBX 1,800 ($22.66) price objective on the stock. in a report on Friday, March 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of GBX 2,373.30 ($29.87).
Hikma Pharmaceuticals Plc (LON:HIK) opened at 1823.00 on Wednesday. Hikma Pharmaceuticals Plc has a one year low of GBX 1,575.00 and a one year high of GBX 2,703.00. The company’s 50-day moving average price is GBX 2,031.78 and its 200-day moving average price is GBX 1,900.31. The firm’s market cap is GBX 4.39 billion.
The firm also recently announced a dividend, which will be paid on Thursday, May 25th. Stockholders of record on Thursday, April 6th will be issued a €0.22 ($0.23) dividend. This is an increase from Hikma Pharmaceuticals Plc’s previous dividend of $0.21. This represents a dividend yield of 0.78%. The ex-dividend date of this dividend is Thursday, April 6th.
TRADEMARK VIOLATION NOTICE: “Hikma Pharmaceuticals Plc’s (HIK) “Neutral” Rating Reiterated at JPMorgan Chase & Co.” was originally reported by Marea Informative and is owned by of Marea Informative. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at http://www.mareainformativa.com/jpmorgan-chase-co-reitera-neutral-clasificacion-para-hikma-pharmaceuticals-plc-hik/108208/.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.